- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05169567
Abemaciclib (LY2835219) plus Fulvestrant im Vergleich zu Placebo plus Fulvestrant bei vorbehandeltem Brustkrebs (postMONARCH)
postMONARCH: Eine randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zum Vergleich der Wirksamkeit von Abemaciclib plus Fulvestrant mit Placebo plus Fulvestrant bei Teilnehmern mit HR-positivem, HER2-, fortgeschrittenem oder metastasiertem Brustkrebs nach Progression unter einem CDK4- und 6-Inhibitor und Endokrin Therapie
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Erweiterter Zugriff
Kontakte und Standorte
Studienorte
-
-
-
San Juan, Argentinien, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentinien, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentinien, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentinien, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentinien, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentinien, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, Belgien, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgien, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, Belgien, 3500
- Jessa Ziekenhuis
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Dänemark, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Dänemark, 7400
- Regionshospitalet Gødstrup
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankreich, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, Frankreich, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankreich, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, Frankreich, 85000
- CHD Vendee
-
-
-
-
-
Thessaloniki, Griechenland, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Griechenland, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Griechenland, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Griechenland, 711 10
- University General Hospital of Heraklion
-
-
-
-
Central District
-
Kfar Saba, Central District, Israel, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israel
- Rabin Medical Center
-
Ramat Gan, Central District, Israel, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israel, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italien, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italien, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italien, 20132
- Ospedale San Raffaele
-
Viterbo, Italien, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italien, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italien, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italien, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexiko, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, Mexiko, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, Mexiko, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, Mexiko, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Polen, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polen, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Schweden, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Schweden, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Badajoz, Spanien, 06006
- Hospital Infanta Cristina
-
Madrid, Spanien, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, Spanien, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Spanien, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Spanien, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spanien, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Spanien, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, Spanien, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, Spanien, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], Spanien, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spanien, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Südkorea, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Südkorea, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Südkorea, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Südkorea, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taiwan, 71004
- Chi Mei Medical Center
-
-
-
-
-
Hradec Králové, Tschechien, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Tschechien, 53203
- Multiscan
-
-
-
-
-
Adana, Türkei (türkiye), 01370
- Adana City Hospital
-
Ankara, Türkei (türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Türkei (türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Türkei (türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Türkei (türkiye), 22030
- Trakya University
-
Istanbul, Türkei (türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Türkei (türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Türkei (türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Türkei (türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
-
Budapest, Ungarn, 1122
- Országos Onkológiai Intézet
-
Budapest, Ungarn, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Ungarn, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Ungarn, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, Vereinigte Staaten, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, Vereinigte Staaten, 92835
- Providence Medical Foundation
-
Los Alamitos, California, Vereinigte Staaten, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Vereinigte Staaten, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, Vereinigte Staaten, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, Vereinigte Staaten, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, Vereinigte Staaten, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, Vereinigte Staaten, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, Vereinigte Staaten, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, Vereinigte Staaten, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, Vereinigte Staaten, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, Vereinigte Staaten, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, Vereinigte Staaten, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, Vereinigte Staaten, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, Vereinigte Staaten, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, Vereinigte Staaten, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, Vereinigte Staaten, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, Vereinigte Staaten, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, Vereinigte Staaten, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, Vereinigte Staaten, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, Vereinigte Staaten, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, Vereinigte Staaten, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, Vereinigte Staaten, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, Vereinigte Staaten, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, Vereinigte Staaten, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, Vereinigte Staaten, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, Vereinigte Staaten, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, Vereinigte Staaten, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, Vereinigte Staaten, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Vereinigte Staaten, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, Vereinigte Staaten, 76022
- Texas Oncology - Bedford
-
Denton, Texas, Vereinigte Staaten, 76201
- Texas Oncology - Denton
-
El Paso, Texas, Vereinigte Staaten, 79902
- Texas Oncology, P.A.
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, Vereinigte Staaten, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, Vereinigte Staaten, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, Vereinigte Staaten, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, Vereinigte Staaten, 75093
- Texas Oncology-Plano West
-
Plano, Texas, Vereinigte Staaten, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Mays Cancer Center
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- US Oncology
-
Tyler, Texas, Vereinigte Staaten, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84107
- Intermountain Medical Center
-
St. George, Utah, Vereinigte Staaten, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, Vereinigte Staaten, 22601
- Shenandoah Oncology, P.C.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Aktiver Komparator: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-Free Survival (PFS)
Zeitfenster: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Zeitfenster: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Zeitfenster: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Neoplastische Prozesse
- Hautkrankheiten
- Brusterkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Haut- und Bindegewebserkrankungen
- Neoplasien der Brust
- Neoplasma Metastasierung
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Polycyclische Verbindungen
- Steroide
- Fusions-Ring-Verbindungen
- Östradiol
- Estrenes
- Estranen
- Östradiol -Kongenere
- Gonadale Steroidhormone
- Gonadalhormone
- Fulvestrant
- Abemaciclib
Andere Studien-ID-Nummern
- 18238
- I3Y-MC-JPEF (Andere Kennung: Eli Lilly and Company)
- 2021-002301-10 (EudraCT-Nummer)
- 2023-506771-10-00 (Andere Kennung: EU Trial Number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-Sharing-Zeitrahmen
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-Sharing-Zugriffskriterien
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .